Total medical devices industry M&A deals worth $28.2bn were announced globally in November 2022, led by Johnson & Johnson’s $16.6bn acquisition of Abiomed, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 619.6% over the previous month of $3.92bn and a rise of 283.8% when compared with the last 12-month average, which stood at $7.35bn.
Comparing M&A deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $28.21bn. At the country level, the US topped the list in terms of deal value at $28.21bn.
In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe top country in terms of M&A deals activity in November 2022 was the US with 26 deals, followed by the Canada with five and the UK with three.
In 2022, as of November, medical devices M&A deals worth $60.99bn were announced globally, marking an increase of 24.04% year on year.
medical devices industry M&A deals in November 2022: Top deals
The top five M&A deals accounted for 99.9% of the overall value during November 2022.
The combined value of the top five medical devices M&A deals stood at $28.19bn, against the overall value of $28.2bn recorded for the month.
The top five medical devices industry M&A deals of November 2022 tracked by GlobalData were:
1) Johnson & Johnson’s $16.6bn acquisition deal with Abiomed
2) The $8.9bn acquisition of Summit Health by VillageMD
3) WerfenLife’s $2bn acquisition deal with Immucor
4) The $615m acquisition of Apollo Endosurgery by Boston Scientific
5) Myriad Genetics’s $75m acquisition deal with Gateway Genomics
